Attached files
file | filename |
---|---|
EX-32.2 - EX-32.2 - Seres Therapeutics, Inc. | mcrb-ex322_9.htm |
EX-32.1 - EX-32.1 - Seres Therapeutics, Inc. | mcrb-ex321_13.htm |
EX-31.2 - EX-31.2 - Seres Therapeutics, Inc. | mcrb-ex312_12.htm |
EX-31.1 - EX-31.1 - Seres Therapeutics, Inc. | mcrb-ex311_7.htm |
EX-10.14 - EX-10.14 - Seres Therapeutics, Inc. | mcrb-ex1014_662.htm |
EX-10.13 - EX-10.13 - Seres Therapeutics, Inc. | mcrb-ex1013_660.htm |
EX-10.12 - EX-10.12 - Seres Therapeutics, Inc. | mcrb-ex1012_659.htm |
EX-10.4 - EX-10.4 - Seres Therapeutics, Inc. | mcrb-ex104_744.htm |
EX-10.1 - EX-10.1 - Seres Therapeutics, Inc. | mcrb-ex101_745.htm |
EX-4.2 - EX-4.2 - Seres Therapeutics, Inc. | mcrb-ex42_661.htm |
10-K - 10-K - Seres Therapeutics, Inc. | mcrb-10k_20201231.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-236824, 333-230092, 333-223514, 333-210171 and 333-205253) and Form S-3 (No.333-244401 and 333-237033) of Seres Therapeutics, Inc. of our report dated March 2, 2021 relating to the financial statements, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
1